New Delhi: Considering the burden on healthcare and the cost of purchasing three doses, zydus cadilla is planning to gain approval for a two-dose dose of its needle-free COVID-19 vaccine, ZyCoV-D. Vaccination was approved by
India’s drug regulator for emergency use in India on 20 August.
Trials are underway for a two-dose regimen. 2mg vaccine has been prescribed in each Dosage modern day
Three-dose vaccine i.e. a total of 6 mg. The company is now evaluating a 2 dosage regimen with 3mg in each dose.
The vaccine is said to be a pioneer because it is the first time that a technologically advanced vaccine has been successfully developed on a plasmid DNA platform for human use.
A plasmid DNA vaccine uses non-replicating DNA molecules. According to Zydus Cadila, the vaccine that when administered produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arm of the human immune system, which plays an important role in protection against disease. Is. As well as viral clearance.
Due to its rapid plug-and-play technology, the platform can be easily adapted to deal with mutations in viruses, such as those already occurring. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually.
The vaccine is stored at 2-8 °C. Unlike Pfizer and Moderna vaccines, which need to be stored at very cold temperatures, ZyCoV-D can be stored at 2 to 8 degrees. This vaccine is also effective against the delta variant of Kovid-19.
ZyCoV-D is needle-free and is administered intradermally using Pharmajet, a needle-free applicator that ensures painless vaccination. This will help in vaccinating children. The vaccine is likely to be available by early October, sources told ANI on Saturday.
Recently in an exclusive interview with ANI, Dr. Sharvil Patel, Managing Director zydus group Said that the supply of vaccine will start from October.
Patel had said, “The supply of vaccine will start by mid-September and from October the supply will be increased to one crore doses per month.”
On the expectation of supplying the vaccine by December, Patel said the company expects to increase by 10 million doses per month from October and will supply 4-5 crore doses per month by January 2022.
“We can increase the production of vaccine to 10 million a month from October at the new production plant, and expect to supply 4-5 million doses by January 2022,” he had said.
According to the Ministry of Health and Family Welfare (MoHFW), with the administration of 72,86,883 vaccine doses in the last 24 hours, the country’s COVID-19 vaccination coverage has crossed the cumulative figure of 73.82Cr (73,82,07,378). Per provisional report by 7 am on Sunday. This has been achieved through 75,25,766 sessions, the ministry said.
Currently, the Covishield, Covaxin, and Sputnik V vaccines are being given to the eligible population above 18 years of age.
India’s drug regulator for emergency use in India on 20 August.
Trials are underway for a two-dose regimen. 2mg vaccine has been prescribed in each Dosage modern day
Three-dose vaccine i.e. a total of 6 mg. The company is now evaluating a 2 dosage regimen with 3mg in each dose.
The vaccine is said to be a pioneer because it is the first time that a technologically advanced vaccine has been successfully developed on a plasmid DNA platform for human use.
A plasmid DNA vaccine uses non-replicating DNA molecules. According to Zydus Cadila, the vaccine that when administered produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arm of the human immune system, which plays an important role in protection against disease. Is. As well as viral clearance.
Due to its rapid plug-and-play technology, the platform can be easily adapted to deal with mutations in viruses, such as those already occurring. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually.
The vaccine is stored at 2-8 °C. Unlike Pfizer and Moderna vaccines, which need to be stored at very cold temperatures, ZyCoV-D can be stored at 2 to 8 degrees. This vaccine is also effective against the delta variant of Kovid-19.
ZyCoV-D is needle-free and is administered intradermally using Pharmajet, a needle-free applicator that ensures painless vaccination. This will help in vaccinating children. The vaccine is likely to be available by early October, sources told ANI on Saturday.
Recently in an exclusive interview with ANI, Dr. Sharvil Patel, Managing Director zydus group Said that the supply of vaccine will start from October.
Patel had said, “The supply of vaccine will start by mid-September and from October the supply will be increased to one crore doses per month.”
On the expectation of supplying the vaccine by December, Patel said the company expects to increase by 10 million doses per month from October and will supply 4-5 crore doses per month by January 2022.
“We can increase the production of vaccine to 10 million a month from October at the new production plant, and expect to supply 4-5 million doses by January 2022,” he had said.
According to the Ministry of Health and Family Welfare (MoHFW), with the administration of 72,86,883 vaccine doses in the last 24 hours, the country’s COVID-19 vaccination coverage has crossed the cumulative figure of 73.82Cr (73,82,07,378). Per provisional report by 7 am on Sunday. This has been achieved through 75,25,766 sessions, the ministry said.
Currently, the Covishield, Covaxin, and Sputnik V vaccines are being given to the eligible population above 18 years of age.
.